These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11390004)

  • 61. Screening for abdominal aortic aneurysm in men ages 60 to 80 years. A cost-effectiveness analysis.
    Frame PS; Fryback DG; Patterson C
    Ann Intern Med; 1993 Sep; 119(5):411-6. PubMed ID: 8338295
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Small and diminutive polyps detected at screening CT colonography: a decision analysis for referral to colonoscopy.
    Pickhardt PJ; Hassan C; Laghi A; Zullo A; Kim DH; Iafrate F; Morini S
    AJR Am J Roentgenol; 2008 Jan; 190(1):136-44. PubMed ID: 18094303
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
    Edelsberg J; Weycker D; Atwood M; Hamilton-Fairley G; Jett JR
    PLoS One; 2018; 13(5):e0197826. PubMed ID: 29787590
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Economic impact of lung cancer screening in France: A modeling study].
    Gendarme S; Perrot É; Reskot F; Bhoowabul V; Fourre G; Souquet PJ; Milleron B; Couraud S
    Rev Mal Respir; 2017 Sep; 34(7):717-728. PubMed ID: 26585377
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease.
    Derdeyn CP; Powers WJ
    Stroke; 1996 Nov; 27(11):1944-50. PubMed ID: 8898796
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost effectiveness of cervical cancer screening for the elderly.
    Fahs MC; Mandelblatt J; Schechter C; Muller C
    Ann Intern Med; 1992 Sep; 117(6):520-7. PubMed ID: 1503355
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective.
    Hagaman JT; Schauer DP; McCormack FX; Kinder BW
    Am J Respir Crit Care Med; 2010 Jun; 181(12):1376-82. PubMed ID: 20167846
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessment of lung cancer mortality reduction after chest X-ray screening in smokers: a population-based cohort study in Varese, Italy.
    Dominioni L; Poli A; Mantovani W; Pisani S; Rotolo N; Paolucci M; Sessa F; Conti V; D'Ambrosio V; Paddeu A; Imperatori A
    Lung Cancer; 2013 Apr; 80(1):50-4. PubMed ID: 23294502
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
    Kwon JS; Lu KH
    Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early Lung Cancer Action Project: overall design and findings from baseline screening.
    Henschke CI; McCauley DI; Yankelevitz DF; Naidich DP; McGuinness G; Miettinen OS; Libby DM; Pasmantier MW; Koizumi J; Altorki NK; Smith JP
    Lancet; 1999 Jul; 354(9173):99-105. PubMed ID: 10408484
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lung cancer screening: is it time for a change in policy?
    Mazzone P; Obuchowski N; Mekhail T; Meziane M; Ahmad M
    Cleve Clin J Med; 2007 Jun; 74(6):441-8. PubMed ID: 17569202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography in an Iranian high-risk population.
    Esmaeili MH; Seyednejad F; Mahboub-Ahari A; Ameri H; Abdollahzad H; Safaei N; Alinezhad F; Yousefi M
    J Med Screen; 2021 Dec; 28(4):494-501. PubMed ID: 34039102
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lung cancer screening: will the controversy extend to its cost-effectiveness?
    Klittich WS; Caro JJ
    Am J Respir Med; 2002; 1(6):393-401. PubMed ID: 14720026
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening.
    Castleberry AW; Smith D; Anderson C; Rotter AJ; Grannis FW
    Br J Cancer; 2009 Sep; 101(6):882-96. PubMed ID: 19690541
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Research Progress on Lung Cancer Screening].
    Guan Y; Ren M; Guo D; He Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):954-960. PubMed ID: 32819054
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Decision analysis for cancer screening in idiopathic venous thromboembolism.
    DI Nisio M; Otten HM; Piccioli A; Lensing AW; Prandoni P; Büller HR; Prins MH
    J Thromb Haemost; 2005 Nov; 3(11):2391-6. PubMed ID: 16241936
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors.
    Lebrett MB; Crosbie EJ; Smith MJ; Woodward ER; Evans DG; Crosbie PAJ
    J Med Genet; 2021 Apr; 58(4):217-226. PubMed ID: 33514608
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland.
    Kanarkiewicz M; Szczęsny TJ; Krysiński J; Buciński A; Kowalewski J; Pawłowicz Z
    Contemp Oncol (Pozn); 2015; 19(6):480-6. PubMed ID: 26843847
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Scan-based competing death risk model for re-evaluating lung cancer computed tomography screening eligibility.
    Schreuder A; Jacobs C; Lessmann N; Broeders MJM; Silva M; Išgum I; de Jong PA; van den Heuvel MM; Sverzellati N; Prokop M; Pastorino U; Schaefer-Prokop CM; van Ginneken B
    Eur Respir J; 2022 May; 59(5):. PubMed ID: 34649976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.